Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Harvard Business School
Merck
McKesson
Julphar
QuintilesIMS
US Army
Cantor Fitzgerald

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,402,609

« Back to Dashboard

Which drugs does patent 7,402,609 protect, and when does it expire?

Patent 7,402,609 protects PATADAY and is included in one NDA.

Protection for PATADAY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in twenty countries.
Summary for Patent: 7,402,609
Title:Olopatadine formulations for topical administration
Abstract:Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
Inventor(s): Castillo; Ernesto J. (Arlington, TX), Han; Wesley Wehsin (Arlington, TX), Zhang; Huixiang (Fort Worth, TX), Bhagat; Haresh G. (Fort Worth, TX), Singh; Onkar N. (Arlington, TX), Bullock; Joseph Paul (Fort Worth, TX), Dixit; Suresh C. (Fort Worth, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:11/079,996
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,402,609
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 7,402,609

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp PATADAY olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,402,609

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,399,508 Olopatadine formulations for topical nasal administration ➤ Sign Up
6,995,186 Olopatadine formulations for topical administration ➤ Sign Up
7,977,376 Olopatadine formulations for topical nasal administration ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Dow
Daiichi Sankyo
QuintilesIMS
Julphar
Covington
Chubb
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.